Two Sigma Advisers LP Acquires 99,900 Shares of Medifast, Inc. (NYSE:MED)

Two Sigma Advisers LP boosted its stake in shares of Medifast, Inc. (NYSE:MED - Free Report) by 86.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 216,000 shares of the specialty retailer's stock after acquiring an additional 99,900 shares during the quarter. Two Sigma Advisers LP owned approximately 1.97% of Medifast worth $3,806,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in MED. Wells Fargo & Company MN boosted its stake in shares of Medifast by 23.5% in the 4th quarter. Wells Fargo & Company MN now owns 6,459 shares of the specialty retailer's stock valued at $114,000 after purchasing an additional 1,227 shares during the last quarter. State of Wyoming raised its position in shares of Medifast by 286.1% in the 4th quarter. State of Wyoming now owns 11,312 shares of the specialty retailer's stock valued at $199,000 after acquiring an additional 8,382 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Medifast by 2,308.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 11,442 shares of the specialty retailer's stock valued at $202,000 after acquiring an additional 10,967 shares during the period. Barclays PLC raised its position in shares of Medifast by 15.1% in the 4th quarter. Barclays PLC now owns 16,194 shares of the specialty retailer's stock valued at $285,000 after acquiring an additional 2,127 shares during the period. Finally, Exchange Traded Concepts LLC raised its position in shares of Medifast by 4.1% in the 4th quarter. Exchange Traded Concepts LLC now owns 17,106 shares of the specialty retailer's stock valued at $301,000 after acquiring an additional 674 shares during the period. Institutional investors own 95.51% of the company's stock.

Wall Street Analysts Forecast Growth

MED has been the topic of a number of analyst reports. DA Davidson cut their price target on shares of Medifast from $17.00 to $16.50 and set a "neutral" rating on the stock in a research report on Wednesday, February 19th. Wall Street Zen upgraded shares of Medifast from a "hold" rating to a "buy" rating in a research report on Thursday, May 1st.

Medifast Stock Performance

MED stock traded up $0.16 during mid-day trading on Friday, hitting $14.10. 238,564 shares of the company were exchanged, compared to its average volume of 287,380. The firm has a market cap of $154.97 million, a P/E ratio of 78.33 and a beta of 0.96. The firm's 50 day simple moving average is $13.05 and its 200 day simple moving average is $15.26. Medifast, Inc. has a 1-year low of $11.57 and a 1-year high of $26.07.

Medifast (NYSE:MED - Get Free Report) last announced its earnings results on Monday, April 28th. The specialty retailer reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04). The company had revenue of $115.73 million for the quarter, compared to analyst estimates of $114.85 million. Medifast had a return on equity of 10.64% and a net margin of 0.35%. On average, equities research analysts predict that Medifast, Inc. will post 0.51 EPS for the current fiscal year.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.